BPCIA UPDATE: ENTROPY IS THE PRICE OF AN ORDERED FRAMEWORK

The pharmaceutical industry has often relied on patent law to protect its investments, recoup costs associated with research and development (e.g., clinical trials), and encourage innovation. Simultaneously, because of patent law's strong protections, a premium is added to drug prices--which li...

Full description

Saved in:
Bibliographic Details
Published in:Berkeley technology law journal 2019-04, Vol.33 (4), p.1277
Main Author: Kulathila, Rithika
Format: Article
Language:English
Subjects:
Access
Affordability
Amendments
Biological products
Clinical research
Clinical trials
Drug prices
Entropy
Flexibility
Incentives
Innovations
Investments
Licensing
Lifesaving
Patent law
Pharmaceutical industry
Prices
R&D
Research & development
Settlements & damages
Supreme courts
Violations
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 4
container_start_page 1277
container_title Berkeley technology law journal
container_volume 33
creator Kulathila, Rithika
description The pharmaceutical industry has often relied on patent law to protect its investments, recoup costs associated with research and development (e.g., clinical trials), and encourage innovation. Simultaneously, because of patent law's strong protections, a premium is added to drug prices--which limits accessibility and affordability to these life-saving therapies. In order to address this concern, Congress created the Hatch-Waxman Amendments in 1984 for small molecule drugs. The Act sought to balance incentives for the pharmaceutical industry as well as increase accessibility and affordability of life-saving drugs for patients. While the Supreme Court settled questions about remedies for statutory violations, the Court's interpretation of the timing of 180-day notice may have some unintended consequences. First, 180-day pre-licensure can lead to parties blindly litigating over controversies that may or may not fully crystallize. Second, by giving the biosimilar manufacturer flexibility on when it can provide 180-day notice, the biosimilar manufacturer may use notice to encourage pay-for-delay settlements.
doi_str_mv 10.15779/Z388P5V921
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2239628321</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2239628321</sourcerecordid><originalsourceid>FETCH-proquest_journals_22396283213</originalsourceid><addsrcrecordid>eNqNyrsOgjAYQOHGaCJeJl_gT5zRXrgUtgolECM0tWp0IQ44ECMK8v46-ABOZ_gOQguCV8T1_WB9YZwr9xhQMkAWZRzbju_QIbII5p7NOOFjNOm6GmNMMWEWCjcqygQcVCyMDEHmRhfqDNkeTCpB6SySUCQgcih0LLWMIdFiJ0-F3s7Q6Ha9d9X81ylaJtJEqf1sm1dfde-ybvr28aWSUhZ4lDNK2H_XBwNqNgg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2239628321</pqid></control><display><type>article</type><title>BPCIA UPDATE: ENTROPY IS THE PRICE OF AN ORDERED FRAMEWORK</title><source>International Bibliography of the Social Sciences (IBSS)</source><source>Nexis UK</source><source>JSTOR Archival Journals and Primary Sources Collection</source><source>BSC - Ebsco (Business Source Ultimate)</source><creator>Kulathila, Rithika</creator><creatorcontrib>Kulathila, Rithika</creatorcontrib><description>The pharmaceutical industry has often relied on patent law to protect its investments, recoup costs associated with research and development (e.g., clinical trials), and encourage innovation. Simultaneously, because of patent law's strong protections, a premium is added to drug prices--which limits accessibility and affordability to these life-saving therapies. In order to address this concern, Congress created the Hatch-Waxman Amendments in 1984 for small molecule drugs. The Act sought to balance incentives for the pharmaceutical industry as well as increase accessibility and affordability of life-saving drugs for patients. While the Supreme Court settled questions about remedies for statutory violations, the Court's interpretation of the timing of 180-day notice may have some unintended consequences. First, 180-day pre-licensure can lead to parties blindly litigating over controversies that may or may not fully crystallize. Second, by giving the biosimilar manufacturer flexibility on when it can provide 180-day notice, the biosimilar manufacturer may use notice to encourage pay-for-delay settlements.</description><identifier>ISSN: 1086-3818</identifier><identifier>EISSN: 2380-4742</identifier><identifier>DOI: 10.15779/Z388P5V921</identifier><language>eng</language><publisher>Berkeley: University of California, Boalt Hall School of Law</publisher><subject>Access ; Affordability ; Amendments ; Biological products ; Clinical research ; Clinical trials ; Drug prices ; Entropy ; Flexibility ; Incentives ; Innovations ; Investments ; Licensing ; Lifesaving ; Patent law ; Pharmaceutical industry ; Prices ; R&amp;D ; Research &amp; development ; Settlements &amp; damages ; Supreme courts ; Violations</subject><ispartof>Berkeley technology law journal, 2019-04, Vol.33 (4), p.1277</ispartof><rights>Copyright University of California, Boalt Hall School of Law Apr 27, 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,33223</link.rule.ids></links><search><creatorcontrib>Kulathila, Rithika</creatorcontrib><title>BPCIA UPDATE: ENTROPY IS THE PRICE OF AN ORDERED FRAMEWORK</title><title>Berkeley technology law journal</title><description>The pharmaceutical industry has often relied on patent law to protect its investments, recoup costs associated with research and development (e.g., clinical trials), and encourage innovation. Simultaneously, because of patent law's strong protections, a premium is added to drug prices--which limits accessibility and affordability to these life-saving therapies. In order to address this concern, Congress created the Hatch-Waxman Amendments in 1984 for small molecule drugs. The Act sought to balance incentives for the pharmaceutical industry as well as increase accessibility and affordability of life-saving drugs for patients. While the Supreme Court settled questions about remedies for statutory violations, the Court's interpretation of the timing of 180-day notice may have some unintended consequences. First, 180-day pre-licensure can lead to parties blindly litigating over controversies that may or may not fully crystallize. Second, by giving the biosimilar manufacturer flexibility on when it can provide 180-day notice, the biosimilar manufacturer may use notice to encourage pay-for-delay settlements.</description><subject>Access</subject><subject>Affordability</subject><subject>Amendments</subject><subject>Biological products</subject><subject>Clinical research</subject><subject>Clinical trials</subject><subject>Drug prices</subject><subject>Entropy</subject><subject>Flexibility</subject><subject>Incentives</subject><subject>Innovations</subject><subject>Investments</subject><subject>Licensing</subject><subject>Lifesaving</subject><subject>Patent law</subject><subject>Pharmaceutical industry</subject><subject>Prices</subject><subject>R&amp;D</subject><subject>Research &amp; development</subject><subject>Settlements &amp; damages</subject><subject>Supreme courts</subject><subject>Violations</subject><issn>1086-3818</issn><issn>2380-4742</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>8BJ</sourceid><recordid>eNqNyrsOgjAYQOHGaCJeJl_gT5zRXrgUtgolECM0tWp0IQ44ECMK8v46-ABOZ_gOQguCV8T1_WB9YZwr9xhQMkAWZRzbju_QIbII5p7NOOFjNOm6GmNMMWEWCjcqygQcVCyMDEHmRhfqDNkeTCpB6SySUCQgcih0LLWMIdFiJ0-F3s7Q6Ha9d9X81ylaJtJEqf1sm1dfde-ybvr28aWSUhZ4lDNK2H_XBwNqNgg</recordid><startdate>20190427</startdate><enddate>20190427</enddate><creator>Kulathila, Rithika</creator><general>University of California, Boalt Hall School of Law</general><scope>8BJ</scope><scope>FQK</scope><scope>JBE</scope></search><sort><creationdate>20190427</creationdate><title>BPCIA UPDATE: ENTROPY IS THE PRICE OF AN ORDERED FRAMEWORK</title><author>Kulathila, Rithika</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_22396283213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Access</topic><topic>Affordability</topic><topic>Amendments</topic><topic>Biological products</topic><topic>Clinical research</topic><topic>Clinical trials</topic><topic>Drug prices</topic><topic>Entropy</topic><topic>Flexibility</topic><topic>Incentives</topic><topic>Innovations</topic><topic>Investments</topic><topic>Licensing</topic><topic>Lifesaving</topic><topic>Patent law</topic><topic>Pharmaceutical industry</topic><topic>Prices</topic><topic>R&amp;D</topic><topic>Research &amp; development</topic><topic>Settlements &amp; damages</topic><topic>Supreme courts</topic><topic>Violations</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kulathila, Rithika</creatorcontrib><collection>International Bibliography of the Social Sciences (IBSS)</collection><collection>International Bibliography of the Social Sciences</collection><collection>International Bibliography of the Social Sciences</collection><jtitle>Berkeley technology law journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kulathila, Rithika</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>BPCIA UPDATE: ENTROPY IS THE PRICE OF AN ORDERED FRAMEWORK</atitle><jtitle>Berkeley technology law journal</jtitle><date>2019-04-27</date><risdate>2019</risdate><volume>33</volume><issue>4</issue><spage>1277</spage><pages>1277-</pages><issn>1086-3818</issn><eissn>2380-4742</eissn><abstract>The pharmaceutical industry has often relied on patent law to protect its investments, recoup costs associated with research and development (e.g., clinical trials), and encourage innovation. Simultaneously, because of patent law's strong protections, a premium is added to drug prices--which limits accessibility and affordability to these life-saving therapies. In order to address this concern, Congress created the Hatch-Waxman Amendments in 1984 for small molecule drugs. The Act sought to balance incentives for the pharmaceutical industry as well as increase accessibility and affordability of life-saving drugs for patients. While the Supreme Court settled questions about remedies for statutory violations, the Court's interpretation of the timing of 180-day notice may have some unintended consequences. First, 180-day pre-licensure can lead to parties blindly litigating over controversies that may or may not fully crystallize. Second, by giving the biosimilar manufacturer flexibility on when it can provide 180-day notice, the biosimilar manufacturer may use notice to encourage pay-for-delay settlements.</abstract><cop>Berkeley</cop><pub>University of California, Boalt Hall School of Law</pub><doi>10.15779/Z388P5V921</doi></addata></record>
fulltext fulltext
identifier ISSN: 1086-3818
ispartof Berkeley technology law journal, 2019-04, Vol.33 (4), p.1277
issn 1086-3818
2380-4742
language eng
recordid cdi_proquest_journals_2239628321
source International Bibliography of the Social Sciences (IBSS); Nexis UK; JSTOR Archival Journals and Primary Sources Collection; BSC - Ebsco (Business Source Ultimate)
subjects Access
Affordability
Amendments
Biological products
Clinical research
Clinical trials
Drug prices
Entropy
Flexibility
Incentives
Innovations
Investments
Licensing
Lifesaving
Patent law
Pharmaceutical industry
Prices
R&D
Research & development
Settlements & damages
Supreme courts
Violations
title BPCIA UPDATE: ENTROPY IS THE PRICE OF AN ORDERED FRAMEWORK
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T19%3A02%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=BPCIA%20UPDATE:%20ENTROPY%20IS%20THE%20PRICE%20OF%20AN%20ORDERED%20FRAMEWORK&rft.jtitle=Berkeley%20technology%20law%20journal&rft.au=Kulathila,%20Rithika&rft.date=2019-04-27&rft.volume=33&rft.issue=4&rft.spage=1277&rft.pages=1277-&rft.issn=1086-3818&rft.eissn=2380-4742&rft_id=info:doi/10.15779/Z388P5V921&rft_dat=%3Cproquest%3E2239628321%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_journals_22396283213%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2239628321&rft_id=info:pmid/&rfr_iscdi=true